Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05651516 · ClinicalTrials.gov registry record · Early Phase 1
Tau PET Imaging in Opioid Use Disorder
A Early Phase 1 study of Opioid-Related Disorders, sponsored by University of Pennsylvania.
- Active
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05651516: Active Early Phase 1 study of Opioid-Related Disorders, sponsored by University of Pennsylvania.
NCT05651516 is a Early Phase 1 study of Opioid-Related Disorders that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 12 participants, below the 347-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05651516, a Early Phase 1 study of Opioid-Related Disorders, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators plan to enroll up to 60 adult subjects in this study. There will be three groups of up to 20 subjects each in this study. Group 1: individuals with OUD and a history of at least one opioid-related OD in the past 5 years that required naloxone treatment reversal: OUD/OD+ Group 2: individuals with OUD without a lifetime history of opioid-related OD OUD/OD- Group 3: Healthy controls without a lifetime OUD: HCs PET/CT imaging will be used to evaluate the uptake of tau in the brain using the investigational radiotracer \[18F\]PI-2620. Each subject will have one \[18F\]PI-2620 positron emission tomography/computed tomography (PET/CT) scan performed.
Conditions Studied
Interventions
- DRUG 18F-PI-2620 PET/CT
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-09-21 |
| Est. Completion | 2027-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05651516
The ClinicalTrials.gov registry entry for NCT05651516 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 347-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (97% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Opioid-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which 18F-PI-2620 PET/CT is the first listed.
NCT05651516 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05651516 about?
NCT05651516 is a clinical study titled "Tau PET Imaging in Opioid Use Disorder". The investigators plan to enroll up to 60 adult subjects in this study. There will be three groups of up to 20 subjects each in this study. Group 1: individuals with OUD and a history of at least one opioid-related OD in the past 5 years that required naloxone treatment reversal: OUD/OD+ Group 2: i...
What is the current status of trial NCT05651516?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2023-09-21. Estimated completion is 2027-12.
What conditions does trial NCT05651516 study?
This clinical trial studies the following conditions: Opioid-Related Disorders.
What interventions are being tested in trial NCT05651516?
The interventions under investigation include: 18F-PI-2620 PET/CT (DRUG).
Who is sponsoring clinical trial NCT05651516?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05651516 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Psilocybin in Cancer Pain Study
RECRUITING · Phase 2
-
Developing and Evaluating a Machine-Learning Opioid Overdose Prediction & Risk-Stratification Tool in Primary Care
RECRUITING · NA
-
Developing a Smartphone Application to Support Veteran Opioid Use Disorder Treatment
RECRUITING · NA
-
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
RECRUITING · Phase 2
-
fMRI and Opioid Abstinence
RECRUITING
-
Outcome Inference in the Sensory Preconditioning Task in Opioid-Use Disorder
RECRUITING
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.